You’ve been with ISPE for 18 years and currently serve as Chair of the ISPE France Affiliate. Can you share some of the highlights of your involvement with the Society during your tenure?

COVID-19 pandemic has caused unprecedented change and disruption to each of our daily lives. All of us around the world are touched by the current pandemic, whether it be personal hardship or professional life challenges. We have seen our communities and our industry rally to work together for the good of public health and humanity. Our ISPE family is no different; several of our local...

COVID-19 pandemic has caused unprecedented change and disruption to each of our daily lives. All of us around the world are touched by the current pandemic, whether it be personal hardship or professional life challenges. We have seen our communities and our industry rally to work together for the good of public health and humanity. Our ISPE family is no different; several of our local...

COVID-19 pandemic has caused unprecedented change and disruption to each of our daily lives. All of us around the world are touched by the current pandemic, whether it be personal hardship or professional life challenges. We have seen our communities and our industry rally to work together for the good of public health and humanity. Our ISPE family is no different; several of our local...

COVID-19 pandemic has caused unprecedented change and disruption to each of our daily lives. All of us around the world are touched by the current pandemic, whether it be personal hardship or professional life challenges. We have seen our communities and our industry rally to work together for the good of public health and humanity. Our ISPE family is no different; several of our local...

Commercially available Advanced Therapy Medicinal Products (ATMPs) are now a reality and significant, rapid growth is expected for new treatments and applications in the clinical development pipeline. By some estimates, from 2014 to 2018, the number of initiated clinical trials grew 32% globally – totaling 1,028 active trials as of end of year 2018 – 92 of which were Phase III.

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to...